Judd Moul, MD, FACS

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (Oncology)
    Ineligible company: 
    Sanofi-Aventis
  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (Oncology)
    Ineligible company: 
    Dendreon
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Bayer
  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (Oncology)
    Ineligible company: 
    Blue Earth Diagnostics
  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (Oncology)
    Ineligible company: 
    Genomic Health
  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (Oncology)
    Ineligible company: 
    Ferring
  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (Oncology)
    Ineligible company: 
    Exosome Dx
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Tolmar
  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (Oncology)
    Ineligible company: 
    Astellas
  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (Oncology)
    Ineligible company: 
    Pfizer

Pages

Return to What's New in the Management of Hormone Naïve & Castrate Resistant Prostate Cancer: A Case-based Session for Urologists, Advanced Practice Providers and Teams Webcast (2021)